Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $2.48 in the prior trading day, Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) closed at $2.41, down -2.82%. In other words, the price has decreased by -$2.82 from its previous closing price. On the day, 1.0 million shares were traded. MRVI stock price reached its highest trading level at $2.57 during the session, while it also had its lowest trading level at $2.41.
Ratios:
Our goal is to gain a better understanding of MRVI by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.17 and its Current Ratio is at 5.96. In the meantime, Its Debt-to-Equity ratio is 1.09 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Goldman Downgraded its Neutral to Sell on December 05, 2024, while the target price for the stock was maintained at $4.25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 ’25 when ORESHACK KURT sold 25,000 shares for $5.03 per share. The transaction valued at 125,750 led to the insider holds 167,618 shares of the business.
ORESHACK KURT bought 25,000 shares of MRVI for $125,750 on Jan 31 ’25. On Nov 12 ’24, another insider, DeFord John A, who serves as the Director of the company, bought 17,500 shares for $5.75 each. As a result, the insider paid 100,625 and bolstered with 70,046 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 880479040 and an Enterprise Value of 672574784. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.54 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 2.781 whereas that against EBITDA is -16.862.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.29, which has changed by -0.74974036 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $10.03, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is 0.77%, while the 200-Day Moving Average is calculated to be -38.14%.
Shares Statistics:
The stock has traded on average 1.77M shares per day over the past 3-months and 1376370 shares per day over the last 10 days, according to various share statistics. A total of 143.96M shares are outstanding, with a floating share count of 103.48M. Insiders hold about 28.13% of the company’s shares, while institutions hold 75.82% stake in the company. Shares short for MRVI as of 1752537600 were 14380643 with a Short Ratio of 8.11, compared to 1749772800 on 13048449. Therefore, it implies a Short% of Shares Outstanding of 14380643 and a Short% of Float of 11.88.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Maravai LifeSciences Holdings Inc (MRVI) reflects the collective analysis of 12.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.03 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.17 and -$0.45 for the fiscal current year, implying an average EPS of -$0.29. EPS for the following year is -$0.23, with 12.0 analysts recommending between -$0.07 and -$0.47.
Revenue Estimates
12 analysts predict $47.37M in revenue for the current quarter. It ranges from a high estimate of $50.8M to a low estimate of $45.2M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $73.4MFor the next quarter, 12 analysts are estimating revenue of $50.08M. There is a high estimate of $53.9M for the next quarter, whereas the lowest estimate is $46.73M.
A total of 13 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $205M, while the lowest revenue estimate was $185.6M, resulting in an average revenue estimate of $194.77M. In the same quarter a year ago, actual revenue was $259.19MBased on 12 analysts’ estimates, the company’s revenue will be $215.57M in the next fiscal year. The high estimate is $234.17M and the low estimate is $201M.
